The way I look at anacea-ei-ei-o-trib's failure....okay, whoop deee do.  Its a positive and a negative.  On the positive side, obviously its good for us, because if RVX-208 gets approved, then its less competition.  But on the down side it shows how hard it is to get a CVD drug/compound through the clinical trial phase and to the finish line. 

Anacetrapib actually made it to the finish line, and still was deemed not viable as a New Drug.  So I can understand a Bio tech centred fund manager having pause about Resverlogix.